Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK and Amira collaborate over development of FLAP inhibitors

GSK and Amira collaborate over development of FLAP inhibitors

7th February 2008

GlaxoSmithKline (GSK) and Amira Pharmaceuticals have confirmed a collaboration agreement that will see the two companies develop, manufacture and commercialise FLAP (5- Lipoxygenase Activating Protein¬) inhibitors for the treatment of respiratory and cardiovascular diseases.

The agreement gives GSK a worldwide licence to Amira’s FLAP inhibitors including lead candidate AM103 and other compounds currently part of the development programme.

The global agreement will initially focus on compound AM103 for the treatment of asthma after early phase I studies already showed the candidate as having potential as a well-tolerated, non-steroidal treatment.

FLAP inhibitors will also be investigated for use in the treatment of other respiratory and cardiovascular indications including rhinitis.

Amira is eligible to receive up to $425 million (215 million pounds) in upfront and milestone payments subject to the successful achievement of all potential development and regulatory milestones.

The pharmaceutical firm is also entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.

Commenting on the introduction of AM103 to the GSK product pipeline, R&D chairman Moncef Slaoui stated: “We believe AM103, a novel FLAP inhibitor, has the potential to offer patients a convenient and effective alternative treatment for respiratory diseases including asthma and rhinitis.”

Also this week, GSK announced that its oral Hycamtin had received a positive opinion from the European Medicines Agency in support of possible marketing authorisation.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.